Abstract:The emergence and re-emergence of pathogens with pandemic potential has been a persistent issue throughout history. Recent decades have seen significant outbreaks of zoonotic viruses from members of the Coronaviridae, Filoviridae, Paramyxoviridae, Flaviviridae, and Togaviridae families, resulting in widespread infections. The continual emergence of zoonotic viral pathogens and associated infections highlights the need for prevention strategies and effective treatments. Central to this effort is the availability of suitable animal models, which are essential for understanding pathogenesis and assessing transmission dynamics. These animals are also critical for evaluating the safety and efficacy of novel vaccines or therapeutics and are essential in facilitating regulatory approval of new products. Rapid development of animal models is an integral aspect of pandemic response and preparedness; however, their establishment is fraught by several rate-limiting steps, including selection of a suitable species, the logistical challenges associated with sharing and disseminating transgenic animals (e.g., the time-intensive nature of breeding and maintaining colonies), the availability of technical expertise, as well as ethical and regulatory approvals. A method for the rapid development of relevant animal models that has recently gained traction, in large part due to the COVID-19 pandemic, is the use of gene therapy vectors to express human viral receptors in readily accessible laboratory animals to enable virus infection and development of clinical disease. These models can be developed rapidly on any genetic background, making mechanistic studies and accelerated evaluation of novel countermeasures possible. In this review, we will discuss important considerations for the effective development of animal models using viral vector approaches and review the current vector-based animal models for studying viral pathogenesis and evaluating prophylactic and therapeutic strategies, with an emphasis on models of SARS-CoV-2 infection based on the vectorized expression of human angiotensin-converting enzyme 2.

Rapidly Deployable Mouse Models of SARS-CoV-2 Infection Add Flexibility to the COVID-19 Toolbox

Human Angiotensin-Converting Enzyme 2 Transgenic Mice Infected with SARS-CoV-2 Develop Severe and Fatal Respiratory Disease

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19

Animal models for COVID-19: advances, gaps and perspectives

Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

Animal and translational models of SARS-CoV-2 infection and COVID-19

A Mouse-adapted SARS-CoV-2 Model for Investigating Post-acute Sequelae of COVID infection

Progress in SARS-CoV-2, Diagnostic and Clinical Treatment of COVID-19

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

A novel pseudovirus‐based mouse model of SARS-CoV-2 infection to test COVID-19 interventions

Rapid Development of Small Rodent Animal Models for Infectious Disease Research Through Vectorized Receptor Molecule Expression

Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator

Animal models for SARS-CoV-2 infection and pathology

A highly susceptible hACE2-transgenic mouse model for SARS-CoV-2 research

Potential mouse models of coronavirus-related immune injury

Cell and animal models of SARS-CoV-2 pathogenesis and immunity

Highly susceptible SARS-CoV-2 model in CAG promoter-driven hACE2-transgenic mice

Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates